Literature DB >> 27238713

Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia.

Stefania Triunfo1, Francesca Crovetto2, Fatima Crispi3, Victor Rodriguez-Sureda4, Carmen Dominguez4, Alfons Nadal5, Anna Peguero3, Eduard Gratacos3, Francesc Figueras3.   

Abstract

OBJECTIVE: To explore in women with late-onset preeclampsia (PE) the association between maternal levels of angiogenic/antiangiogenic factors in the first trimester of pregnancy and histological findings attributable to placental underperfusion (PUP).
METHODS: A nested case-control cohort study was conducted in 73 women with pregnancies complicated by late-onset PE (>34 weeks at delivery) matched with controls. First trimester uterine artery Doppler (UtA); maternal levels of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) were retrieved. Placentas were histologically evaluated using a hierarchical and standardized classification system. One-way ANOVA with linear polynomial contrast or linear-by-linear association test was performed to test the hypothesis of a linear association across study groups (controls, PE without PUP and PE with PUP).
RESULTS: In 54 (74%) placentas, 89 placental histological findings qualifying for PUP were found. Across study groups, significant values were observed in maternal levels of decreased PlGF (MoM values: 1.53, 1.41 and 1.37; p < 0.001), increased sFlt-1 (MoM values: 3.11, 3.11 and 3.22; p = 0.002), increased sFlt-1/PlGF ratio (MoM values: 2.3, 2.3 and 2.44; p < 0.001), abnormal UtA Doppler (MoM values: 1, 1.26 and 1.32; p < 0.001), and worse perinatal outcomes in terms of gestational age at delivery, cesarean section for not reassuring fetal status, birth weight and neonatal acidosis. DISCUSSION: In late-onset PE an imbalance of circulating angiogenic and anti-angiogenic factors already present at 8-10 weeks of pregnancy was associated with histological findings reflecting placental insufficiency. An early first trimester screening by angiogenic factors might help to identify patients with placental involvement among late-onset PE cases.
CONCLUSION: In late-onset preeclampsia, first-trimester uterine Doppler and circulating levels of angiogenic/antiangiogenic factors are associated with placental underperfusion.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  First trimester screening; Histological findings; Placental growth factor; Placental underperfusion; Preeclampsia; Soluble fms-like tyrosine kinase-1

Mesh:

Substances:

Year:  2016        PMID: 27238713     DOI: 10.1016/j.placenta.2016.04.005

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  4 in total

1.  Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia.

Authors:  Jennifer L Sones; Audrey A Merriam; Angelina Seffens; Dex-Ann Brown-Grant; Scott D Butler; Anna M Zhao; Xinjing Xu; Carrie J Shawber; Jennifer K Grenier; Nataki C Douglas
Journal:  FASEB J       Date:  2018-01-08       Impact factor: 5.191

2.  Celecoxib restores angiogenic factor expression at the maternal-fetal interface in the BPH/5 mouse model of preeclampsia.

Authors:  Dorien Reijnders; Chin-Chi Liu; Xinjing Xu; Anna M Zhao; Kelsey N Olson; Scott D Butler; Nataki C Douglas; Jenny L Sones
Journal:  Physiol Genomics       Date:  2018-03-09       Impact factor: 3.107

3.  Early second trimester maternal serum markers in the prediction of gestational diabetes mellitus.

Authors:  Baihui Zhao; Xiujun Han; Qing Meng; Qiong Luo
Journal:  J Diabetes Investig       Date:  2018-01-28       Impact factor: 4.232

4.  Association of mid-trimester maternal angiogenic biomarkers with small-for-gestational-age infants in an urban Zambian cohort: a nested case-control study.

Authors:  Chileshe M Mabula-Bwalya; Megan E Smithmyer; Humphrey Mwape; Gabriel Chipili; Madelyn Conner; Bellington Vwalika; Kristina De Paris; Jeffrey S A Stringer; Joan T Price
Journal:  Int J Gynaecol Obstet       Date:  2021-08-25       Impact factor: 4.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.